Lignocaine

Dosage ; See below

Lignocaine Brands

Brand Name Manufacturer Name Distributor Drug Strength Packaging Formulation Formulation Strength Price
Dawacaine Plus Dawa Limited Dawa Limited 2% 30ml Injection per ml KES 30
Dawacaine Dawa Limited Dawa Limited 50mg/20mg 30ml Injection per ml KES 20.00
Dawacaine Dawa Limited Dawa Limited 2% 30ml Injection per ml KES 20.00
Lignocaine Laborate Harley's Limited 50mg/20mg 30ml Injection per ml KES 18
Lignocaine Laborate Harley's Limited 50mg/20mg 5ml Injection per ml KES 856
Lignocaine Laborate Harley's Limited 50mg/20mg 20ml Injection per ml KES 1239
Lignocaine Laborate Harley's Limited 2% 30ml Injection per ml KES 27.50
Lignocaine Laborate Harley's Limited 2% 50 x 30ml Injection per ml KES 1200
Locaine A Adcock ingram E.A. Adcock ingram E.A. 2% 1.8mlx100?s Injection per ml KES 2,941
Lox Heavy Neon Laboratories Ltd Sai Pharmaceuticals Ltd. 5% 10's x 2ml Injection per ml KES 588.00
Lox Neon Laboratories Ltd Sai Pharmaceuticals Ltd. 2% 30ml Injection per ml KES 103.00
Lox Neon Laboratories Ltd Sai Pharmaceuticals Ltd. 2% 50ml Injection per ml KES 158.00
Sensinil Claris Lifesciences Ltd. Pan Pharmaceuticals Ltd 2% 30ml Injection per ml KES 35.00
Xylocaine AstraZeneca Radiance Pharmaceuticals Limited 10% 50ml Injection per ml KES 2,199
Xylocaine AstraZeneca Radiance Pharmaceuticals Limited 10% 30g x10's Injection per ml KES 852
Xylocaine AstraZeneca Radiance Pharmaceuticals Limited 5% 35gm Ointment KES 893.00
Xylocaine AstraZeneca Radiance Pharmaceuticals Limited 10% 50ml spray KES 2,320.00
Anesthine Prism Life Sciences Galaxy Pharmaceuticals Ltd 2% 30ml Injection per vial KES 35.00
Lido Prism Life Sciences Galaxy Pharmaceuticals Ltd 2% 30ml Injection per vial KES 30.00
Lidocaine Macs Pharmaceuticals Mac?s Pharmaceuticals Ltd 2% 30ml Injection per vial KES 25.00
Lignocaine Fresenius Surgipharm Ltd 2% 50ml Injection per vial KES 856.00
Lignocaine Fresenius Surgipharm Ltd 2% 200ml Injection per vial KES 1,450.00

Lignocaine More info
Mode Of Action

Class I anti-arrhythmic agent.
Drug Indication Local anaesthesia; parenterally for the acute treatment of ventricular arrhythmias occurring after myocardial infarction or during cardiac procedures such as cardiac surgery or cardiac catheterization; drug of choice for the treatment of ventricular premature contractions (VPCs) associated with myocardial infarction; status epilepticus as a last resort.
Precautions ECG monitoring is necessary during its IV administration; liver disease, congestive heart failure, marked hypoxia, severe respiratory depression, hypovolemia, or shock; administering lidocaine to patients with sinus bradycardia or incomplete heart block for the treatment of ventricular premature contractions without prior acceleration of heart rate; fibrillation.
Contra-Indications Known hypersensitivity to the amide-type local anesthetics; patients with Adams-Stokes syndrome or with severe degrees of SA, AV, or intraventricular heart block in the absence of an artificial pacemaker.
Side Effects Serious side effects are uncommon. Drowsiness; dizziness; disorientation; confusion; lightheadedness; psychosis; apprehension; tinnitus; visual disturbances including amblyopia or diplopia; nausea; vomiting; paraesthesia; sensations of heat, cold, or numbness; difficulty swallowing; dyspnea; and slurred speech; muscle twitching or tremors, seizures, unconsciousness, coma, and respiratory depression; hypersensitivity reaction; hypotension, arrhythmias, heart block; local thrombophlebitis.
Special Information Use of lidocaine with adrenaline prolongs its duration of action and prevents its widespread to non-required areas.
Pregnancy Category Category A1:
Pregnancy Category Description Drugs which have been taken by a sizeable number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted.
Drug Category DRUGS ACTI NG ON THE CARDIO-VASCULAR SYSTEM
Drug Sub-Category Ventricular anti-arrhythmics

Dosing: Adult

Antiarrhythmic (ACLS, 2010):

VF or pulseless VT (after defibrillation attempts, CPR, and vasopressor administration) if amiodarone is not available: I.V., intraosseous (I.O.): Initial: 1-1.5 mg/kg. If refractory VF or pulseless VT, repeat 0.5-0.75 mg/kg bolus every 5-10 minutes (maximum cumulative dose: 3 mg/kg). Follow with continuous infusion (1-4 mg/minute) after return of perfusion. Reappearance of arrhythmia during constant infusion: 0.5 mg/kg bolus and reassessment of infusion (Zipes, 2000)

Intratracheal (loading dose only): 2-3.75 mg/kg (2-2.5 times the recommended I.V. dose); dilute in 5-10 mL NS or sterile water. Note: Absorption is greater with sterile water and results in less impairment of PaO2.

Hemodynamically stable monomorphic VT: I.V.: 1-1.5 mg/kg; repeat with 0.5-0.75 mg/kg every 5-10 minutes as necessary (maximum cumulative dose: 3 mg/kg). Follow with continuous infusion of 1-4 mg/minute or 30-50 mcg/kg/minute

Note: Dose reduction (eg, of maintenance infusion) necessary in patients with CHF, shock, or hepatic disease.

Anesthesia, local injectable: Varies with procedure, degree of anesthesia needed, vascularity of tissue, duration of anesthesia required, and physical condition of patient; maximum: 4.5 mg/kg/dose not to exceed 300 mg; do not repeat within 2 hours.

Dosing: Pediatric

Antiarrhythmic (PALS, 2010):

I.V., intraosseous (I.O.): Note: For use in VF or pulseless VT if amiodarone is not available; give after defibrillation attempts, CPR, and epinephrine:

Loading dose: 1 mg/kg; follow with continuous infusion; may administer second bolus of 0.5-1 mg/kg if delay between bolus and start of infusion is >15 minutes (PALS, 2000)

Continuous infusion: 20-50 mcg/kg/minute. Per the manufacturer, use a maximum of 20 mcg/kg/minute in patients with shock, hepatic disease, cardiac arrest, or CHF

Intratracheal: 2-3 mg/kg; flush with 5 mL of NS and follow with 5 assisted manual ventilations

Anesthesia, local injectable: Refer to adult dosing.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment

Not dialyzable (0% to 5%) by hemo- or peritoneal dialysis; supplemental dose is not necessary.

Dosing: Hepatic Impairment

Dose reduction (eg, of maintenance infusion) necessary in patients with hepatic impairment; monitor lidocaine concentrations closely